These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 25163397

  • 1. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.
    Broom RJ, Hinder V, Sharples K, Proctor J, Duffey S, Pollard S, Fong PC, Forgeson G, Harris DL, Jameson MB, O'Donnell A, North RT, Deva S, Hanning FJ, Grey A, Findlay MP.
    Clin Genitourin Cancer; 2015 Feb; 13(1):50-8. PubMed ID: 25163397
    [Abstract] [Full Text] [Related]

  • 2. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
    Lipton A, Zheng M, Seaman J.
    Cancer; 2003 Sep 01; 98(5):962-9. PubMed ID: 12942563
    [Abstract] [Full Text] [Related]

  • 3. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.
    Zhao X, Xu X, Guo L, Ragaz J, Guo H, Wu J, Shao Z, Zhu J, Guo X, Chen J, Zhu B, Wang Z, Hu X.
    Breast Cancer Res Treat; 2010 Dec 01; 124(3):733-43. PubMed ID: 20882405
    [Abstract] [Full Text] [Related]

  • 4. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
    Lipton A, Cook RJ, Major P, Smith MR, Coleman RE.
    Oncologist; 2007 Sep 01; 12(9):1035-43. PubMed ID: 17914073
    [Abstract] [Full Text] [Related]

  • 5. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C, Kuchuk I, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Dranitsaris G, Dent S, Gertler S, Verma S, Song X, Simos S, Cella D, Clemons M.
    Breast Cancer Res Treat; 2016 Jan 01; 155(1):77-84. PubMed ID: 26643085
    [Abstract] [Full Text] [Related]

  • 6. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE.
    J Clin Oncol; 2006 Oct 20; 24(30):4895-900. PubMed ID: 17001071
    [Abstract] [Full Text] [Related]

  • 7. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
    Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 2):6397S-403S. PubMed ID: 15448038
    [Abstract] [Full Text] [Related]

  • 8. Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis.
    Izumi K, Mizokami A, Itai S, Shima T, Shigehara K, Miwa S, Maeda Y, Konaka H, Koh E, Namiki M.
    BJU Int; 2012 Feb 15; 109(3):394-400. PubMed ID: 21599822
    [Abstract] [Full Text] [Related]

  • 9. [Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
    Hu XY, Zou QF, Jin C, Li WD, Chen WS, Ma L.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun 15; 30(6):1343-6. PubMed ID: 20584674
    [Abstract] [Full Text] [Related]

  • 10. Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: more than a 24-month median follow-up.
    Takeda N, Isu K, Hiraga H, Shinohara N, Minami A, Kamata H.
    J Orthop Sci; 2012 Nov 15; 17(6):770-4. PubMed ID: 23053582
    [Abstract] [Full Text] [Related]

  • 11. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.
    Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M.
    Int J Clin Oncol; 2010 Aug 15; 15(4):382-9. PubMed ID: 20354750
    [Abstract] [Full Text] [Related]

  • 12. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
    Tunn UW, Stenzl A, Schultze-Seemann W, Strauss A, Kindler M, Miller K, Wirth MP, Zantl N, Schulze M, May C, Ruebel A, Birkholz K, Gruenwald V.
    Can J Urol; 2012 Jun 15; 19(3):6261-7. PubMed ID: 22704310
    [Abstract] [Full Text] [Related]

  • 13. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.
    Lipton A, Fizazi K, Stopeck AT, Henry DH, Smith MR, Shore N, Martin M, Vadhan-Raj S, Brown JE, Richardson GE, Saad F, Yardley DA, Zhou K, Balakumaran A, Braun A.
    Eur J Cancer; 2016 Jan 15; 53():75-83. PubMed ID: 26693901
    [Abstract] [Full Text] [Related]

  • 14. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
    Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S.
    J Clin Oncol; 2009 Apr 01; 27(10):1564-71. PubMed ID: 19237632
    [Abstract] [Full Text] [Related]

  • 15. Prospective Evaluation of Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma.
    Orita Y, Sugitani I, Takao S, Toda K, Manabe J, Miyata S.
    Ann Surg Oncol; 2015 Nov 01; 22(12):4008-13. PubMed ID: 25762482
    [Abstract] [Full Text] [Related]

  • 16. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
    Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J.
    Cancer; 2004 Jun 15; 100(12):2613-21. PubMed ID: 15197804
    [Abstract] [Full Text] [Related]

  • 17. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.
    Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M, Lipton A.
    JAMA Oncol; 2017 Jul 01; 3(7):906-912. PubMed ID: 28125763
    [Abstract] [Full Text] [Related]

  • 18. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
    Bachmann G, Kriegman A, Gonçalves J, Kianifard F, Warren M, Simon JA.
    Menopause; 2011 Aug 01; 18(8):851-6. PubMed ID: 21796066
    [Abstract] [Full Text] [Related]

  • 19. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 01; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 20. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
    Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergström B.
    Ann Oncol; 2007 Jul 01; 18(7):1165-71. PubMed ID: 17442659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.